Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Gains from Investment Securities (2020 - 2024)

Historic Gains from Investment Securities for HCW Biologics (HCWB) over the last 5 years, with Q4 2024 value amounting to $14484.0.

  • HCW Biologics' Gains from Investment Securities fell 9226.66% to $14484.0 in Q4 2024 from the same period last year, while for Dec 2021 it was $1.8 million, marking a year-over-year increase of 13862.9%. This contributed to the annual value of $1.8 million for FY2024, which is 26.4% up from last year.
  • According to the latest figures from Q4 2024, HCW Biologics' Gains from Investment Securities is $14484.0, which was down 9226.66% from $187292.0 recorded in Q4 2023.
  • In the past 5 years, HCW Biologics' Gains from Investment Securities registered a high of $1.8 million during Q4 2021, and its lowest value of $14484.0 during Q4 2024.
  • Its 5-year average for Gains from Investment Securities is $589172.6, with a median of $231301.0 in 2022.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first surged by 13862.9% in 2021, then plummeted by 9226.66% in 2024.
  • Quarter analysis of 5 years shows HCW Biologics' Gains from Investment Securities stood at $742047.0 in 2020, then soared by 138.63% to $1.8 million in 2021, then tumbled by 86.94% to $231301.0 in 2022, then fell by 19.03% to $187292.0 in 2023, then tumbled by 92.27% to $14484.0 in 2024.
  • Its Gains from Investment Securities stands at $14484.0 for Q4 2024, versus $187292.0 for Q4 2023 and $231301.0 for Q4 2022.